期刊文献+

药物基因组学与个性化药物设计研究进展 被引量:3

Progress of Pharmacogenomics and Individual Drug Design
下载PDF
导出
摘要 药物基因组学是采用基因组学的信息和研究方法,通过分析DNA的遗传变异和监测基因表达谱,以阐明药物反应差异的遗传学本质。这不仅有利于根据药物代谢和药物反应的遗传学特点指导合理用药,而且有利于开发和设计新的药物。综述药物基因组学研究进展,论述与药物开发和临床用药相关的药物代谢的基因组学原理,给出CYP450、药物转运蛋白等实例,概述药物基因组学的一些潜在的用途,预测药物基因组学的发展和临床应用前景。 Pharmacogenomics is a branch studying how an individual genetic inheritance affects the body's response to drugs. A goal of pharmacogenomics is to guide the drug design and discovery so as to optimize the therapeutic benefit and minimize the potential toxicity. Genetic-based differences in drug metabolism have long been recognized but just now are on the verge of wider clinical application. Differences in efficacy of drugs based on common genetic variations (polymorphisms) only recently have started to be explored, but the potential for clinical application and drug development appears promising. This review describes some of the recent advances in pharmacogenomics research. The principles of pharmacogenomics applied to drug metabolism that are relevant to the drug development and clinical use were discussed, and examples were given for CYP450 enzymes and drug transporters. The current and future clinical potential was summarized. The rapid research progresses and initial clinical applications of oharmacogenomics were also foreseen in the near future.
出处 《药学进展》 CAS 2007年第6期241-246,共6页 Progress in Pharmaceutical Sciences
关键词 药物基因组学 药物遗传学 最优化治疗 药物开发 Phannacogenomics Phannacogenetics Optimized therapeutics Drug development
  • 相关文献

参考文献16

二级参考文献81

  • 1魏尔清.药理学前沿[M].北京:科学出版社,1999.286-287.
  • 2崔昕.药物基因组学沟通中西医对话[N].中国医药报(医疗科教版),2002-10-29(11).
  • 3Tai H-L,Krynetski EY,Schuete3 EG,et al. Enhanced proteolysis of thiopurine s-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A,TPMT*2):mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA,1997,94:6444-6449.
  • 4Hoffmeyer S, Burk O, Richter O, et al. Functional polymorphisms of the human multiclrug-resistance gene:multiple sequence variations and correlation of the allele with P-glycoprotein expression and activitu in vivo. Proc Natl Acad Sci USA, 2000,97:3473-34
  • 5Fellovy J,Marzolini C,Meadren ER. Response to antiretroviral tretmant in HIV-I infected individuals with allele variants of the multidrug resistance transporter 1 :a pharmacogenetics study. Lancet,2002,359: 30-36.
  • 6Kuivenhoven JA,Jukema JW,Zwinderman AH,et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosderosis. N Engl J Med, 1998,338:86-93.
  • 7Abbott GW,Sesti F,Splawski I,et al. MIRP1 forms Ikr potassium channels with HERG and is associated with cardiac arrhythmia.Cell, 1999,97:175-187.
  • 8Weinshilboum RM,Sladek SL. Mercaptopurine pharmacogenetics:monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Ann J Hum Genet,1980,32:19-52.
  • 9Brinkmann U,Roots I,Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDRI:impact of polymorphisms on phannacotherapy. Drug Discov Today,2001,6:835-839.
  • 10Schuet3 JD,Connelly Mc,Sun D,et al. MRP4:a previously unidentiffed factor in resistance to nucleoside-based antiviral drugs. Nat Med, 1999,5:1048-1051.

共引文献46

同被引文献12

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部